First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study

Translational Oncology

Volumn 5, Issue 1, 2012, Pages 32-38

  Karlsson, Jan Olof G ^a,b   Adolfsson, Karin ^c   Thelin, Bo ^c   Jynge, Per ^a,b   Andersson, Rolf G G ^a   Falkmer, Ursula G ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b PledPharma AB   (Sweden)

^c RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CONTRAST MEDIUM; FLUOROURACIL; LEVOLEUCOVORIN; MANGAFODIPIR; ONDANSETRON; OXALIPLATIN; PLACEBO; SUPEROXIDE DISMUTASE;

ADD ON THERAPY; ADJUVANT THERAPY; ADVERSE DRUG REACTION; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DIARRHEA; DRUG MARKETING; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREMEDICATION; RANDOMIZED CONTROLLED TRIAL; TRANSLATIONAL RESEARCH; VOMITING;

EID: 84855992374     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11277     Document Type: Article

References (23)

1. O'Neil BH and Goldberg RM (2008). Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 13, 1074-1083.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, and Boyle P (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18, 581-592.
3. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350, 2343-2351.
4. McWhinney SR, Goldberg RM, and McLeod HL (2009). Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8, 10-16.
5. 2-induced endothelium-dependent relaxation in bovine mesenteric arteries. J Pharmacol Exp Ther 271, 609-618.
6. Karlsson JOG, Brurok H, Eriksen M, Towart R, Toft KG, Moen O, Engebretsen B, Jynge P, and Refsum H (2001). Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium. Acta Radiol 42, 540-547.
7. Smith HJ (2001). Contrast-enhanced MR imaging in the diagnosis and preservation of cardiac viability [editorial]. Acta Radiol 42, 539.
8. Doroshow JH (2006). Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity [editorial]. J Natl Cancer Inst 98, 223-225.
9. Bedda S, Laurent A, Conti F, Chéreau C, Tran A, Tran-Van Nhieu J, Jaffray P, Soubrane O, Goulvestre C, Calmus Y, et al. (2003). Mangafodipir prevents liver injury induced by acetaminophen in the mouse. J Hepatol 39, 765-772.
10. Karlsson JOG (2004). Antioxidant activity of mangafodipir is not a new finding [letter to the editor]. J Hepatol 40, 872-873.
11. Alexandre J, Nicco C, Chéreau C, Laurent A, Weill B, Goldwasser F, and Batteux F (2006). Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 98, 236-244.
12. Karlsson JOG, Brurok H, Towart R, and Jynge P (2006). The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activity [letter to the editor]. Cancer Res 66, 598.
13. Laurent A, Nicco C, Chéreau C, Goulvestre C, Alexandre J, Alves A, Lévy E, Goldwasser F, Panis Y, Soubrane O, et al. (2005). Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65, 948-956.
14. Yri OE, Vig J, Hegstad E, Hovde O, Pignon I, and Jynge P (2009). Mangafodipir as a cytoprotective adjunct to chemotherapy-a case report. Acta Oncol 48, 633-635.
15. Brurok H, Ardenkjaer-Larsen JH, Hansson G, Skarra S, Berg K, Karlsson JO, Laursen I, and Jynge P (1999). Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties. Biochem Biophys Res Commun 254, 768-772.
16. Rocklage SM, Cacheris WP, Quay SC, Hahn FE, and Raymond KN (1989). Manganese(II) N,N ′-dipyridoxylethylenediamine-N,N ′-diacetate 5,5′-bis (phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem 28, 477-485.
17. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, and Thompson JA (1996). Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 93, 11853-11858.
18. Agarwal R, Macmillan-Crow LA, Rafferty TM, Saba H, Roberts DW, Fifer EK, James LP, and Hinson JA (2010). Acetaminophen-induced hepatotoxicity in mice occurs with inhibition of activity and nitration of mitochondrial manganese superoxide dismutase. J Pharmacol Exp Ther 337, 110-118.
19. Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J, Segura A, and Gómez-Codina J (2006). Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol 23, 347-357.
20. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, and Loprinzi CL (2002). Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20, 1491-1498.
21. Fernández-Lobato B, Díaz-Carrasco MS, Pareja A, Marín M, Vila N, and de la Rubia A (2009). Therapeutic use and profile of toxicity of the FOLFOX4 regimen. Farm Hosp 33, 89-95.
22. Lyman GH (2006). Chemotherapy dose intensity and quality cancer care. Oncology 20(suppl 9), 16-25.
23. Lyman GH (2009). Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 7, 99-108.